Hence, the high potentiality of our recombinant molecule has been confirmed by the fact that CTX-CNF1 was found to have similar effects on three different preclinical glioma models (i.e., GL261, U87 and PDGF+ TRP53−/−). The gene discussed is TP53; the disease is glioma.